Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of SIM0718 in adolescents and adults with moderate-to-severe atopic dermatitis
CTR20242160Phase 3Completed
- Sponsor
- 苏州康乃德生物医药有限公司
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atopic dermatitis (AD) comparing SIM0718 with Placebo to SIM0718 (2 arms). Primary endpoints: Proportion of participants achieving EASI-75 at week 16 and Investigator's Global Assessment response rate at week 16. Started Jun 2024; status: completed.
02
Drugs
rademikibart
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20242160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242160.